<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01975441</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU 3 vs 2 LF ELIM PNG</org_study_id>
    <nct_id>NCT01975441</nct_id>
  </id_info>
  <brief_title>Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa</brief_title>
  <official_title>Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if a combination of 3 drugs used to treat the infection that cause
      lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing
      or sterilizing the adult worms compared to just 2 of the 3 drugs that usually given to treat
      this infection. The three drugs used together are called albendazole (ALB), ivermectin (IVM)
      and diethylcarbamazine (DEC). The usual treatment in Papua New Guinea (PNG) for lymphatic
      filariasis are DEC and ALB. A combination of these 3 drugs has not been previously used to
      treat LF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will determine whether 1 or 2 annual treatments with the triple drug regimen of
      DEC/Iver/Alb is equally or more effective than repeated annual treatments with DEC/Alb in
      inducing sustained clearance of Mf in LF infected subjects previously determined to have
      &gt;100Mf/ml, indicative of a moderate to heavy infection. Subjects will be treated and
      monitored in several common areas near study subject residences.

      There will be 3 treatment arms as follows:

        1. The comparator (standard treatment) DEC 6 mg/kg + Alb 400 mg administered annually (at
           0, 12, and 24 months).

        2. DEC 6 mg/kg + Alb 400 mg given once

        3. DEC 6 mg/kg + Alb 400 mg + Iver 200 µg/kg administered once only at the beginning of the
           RCT (0 month).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with total clearance of in Wuchereria bancrofti (Wb) microfilaria (mf)</measure>
    <time_frame>at 36 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Lymphatic Filariasis</condition>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEC 6 mg/kg + Alb 400 mg x 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEC + ALB + IVM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylcarbamazine</intervention_name>
    <description>Diethylcarbamazine 6mg/kg</description>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_label>DEC 6 mg/kg + Alb 400 mg x 1</arm_group_label>
    <arm_group_label>DEC + ALB + IVM</arm_group_label>
    <other_name>DEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Albendazole 400mg</description>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_label>DEC 6 mg/kg + Alb 400 mg x 1</arm_group_label>
    <arm_group_label>DEC + ALB + IVM</arm_group_label>
    <other_name>ALB, Albenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Ivermectin 200 mcg/kg</description>
    <arm_group_label>DEC + ALB + IVM</arm_group_label>
    <other_name>IVM, Stromectol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18-65 years

          -  &gt;100mf/ml in finger stick blood samples

          -  Willing to give informed consent

        Exclusion Criteria:

          -  Prior treatment for LF within last 5 years

          -  Pregnant (do pregnancy test)

          -  Hemoglobin &lt; 7 g/dl

          -  permanent disability, serious medical illness that prevents or impedes study
             participation and/or comprehension

          -  AST/ALT and creatinine &gt; 1.5 upper limit of normal.

          -  Urine dipstick with glucose ≥ 2+ and/or protein ≥ 2+
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Siba, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Papua New Guinea Institution for Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Papua New Guinean Institute for Medical Research</name>
      <address>
        <city>Maprik</city>
        <state>East Sepik</state>
        <country>Papua New Guinea</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Papua New Guinea</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2013</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Christopher L. King, MD, PhD</investigator_full_name>
    <investigator_title>Professor/PI</investigator_title>
  </responsible_party>
  <keyword>Diethycarbamazine</keyword>
  <keyword>Albendazole</keyword>
  <keyword>Ivermectin</keyword>
  <keyword>Lymphatic filariasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
    <mesh_term>Elephantiasis, Filarial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Diethylcarbamazine</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

